COVID-19 Vaccine: AstraZeneca AZD1222 phase 1/2 trials to begin in Japan

Published On 2020-09-06 03:45 GMT | Update On 2020-09-06 03:45 GMT

Tokyo: Astrazeneca said on Friday it is beginning Phase 1/2 clinical trials in Japan of its coronavirus vaccine candidate.

Trials of the vaccine, known as AZD1222, will be conducted at multiple facilities in Japan, targeting 250 subjects, the company said in a release.

Read also: AstraZeneca COVID vaccine reached Phase 3 clinical trials in US: Trump

The British company is working with Daiichi Sankyo, JCR Pharma and other partners in Japan to make and distribute the vaccine.

Read also:AstraZeneca diabetes drug dapagliflozin shows significant benefits in CKD patients

Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

COVID-19 Vaccine: AstraZeneca AZD1222 phase 1/2 trials to begin in Japan

Similar News